Purpose: Patients with HER2-positive metastatic breast tor–negative disease, had higher risk of CNS metastasis. cancer (MBC) with central nervous system (CNS) metastasis Patients with CNS metastasis at diagnosis received first-line have a poor prognosis. We report treatments and outcomes in lapatinib more commonly (23.0% vs. 2.5%), and trastuzumab patients with HER2-positive MBC and CNS metastasis from less commonly (70.1% vs. 92.8%), than patients without CNS the Systemic Therapies for HER2-positive Metastatic Breast metastasis at diagnosis. Risk of death was higher with CNS Cancer Study (SystHERs). metastasis observed at or after diagnosis [median overall Experimental Design: SystHERs (NCT01615068) was a survival (OS) 30.2 and 38.3 months from MBC diagnosis, prospective, U.S.-based, observational registry of patients with respectively] versus no CNS metastasis [median OS not esti-newly diagnosed HER2-positive MBC. Study endpoints mable: HR 2.86; 95% confidence interval (CI), 2.05–4.00 and included treatment patterns, clinical outcomes, and patient-HR 1.94; 95% CI, 1.52–2.49]. Patients with versus without reported outcomes (PRO). CNS metastasis at diagnosis had lower quality of life at Results: Among 977 eligible patients enrolled (2012–enrollment. 2016), CNS metastasis was observed in 87 (8.9%) at initial Conclusions: Despite advances in HER2-targeted treatments, MBC diagnosis and 212 (21.7%) after diagnosis, and was not patients with CNS metastasis continue to have a poor prognosis observed in 678 (69.4%) patients. White and younger and impaired quality of life. Observation of CNS metastasis patients, and those with recurrent MBC and hormone recep-appears to influence HER2-targeted treatment choice.
ASJC Scopus subject areas
- Cancer Research